Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
SUTRO BIOPHARMA, INC. (STRO) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
10/04/2023 8-K Entry into a Material Definitive Agreement  Interactive Data
08/25/2023 144 Form 144 - Report of proposed sale of securities:
08/11/2023 4 Chung Jane (Chief Commercial Officer) has filed a Form 4 on SUTRO BIOPHARMA, INC.
Txns: Paid exercise price by delivering 6,483 shares @ $4.22, valued at $27.4k
Exercised 18,750 restricted stock units @ $0
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/10/2023 8-K Quarterly results
Docs: "Sutro Biopharma Reports Second Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones - Enrollment is underway for REFRaME-O1, the Phase 2/3 pivotal study of luveltamab tazevibulin, or luvelta, for patients with platinum-resistant ovarian cancer - - Sutro will present data from the Phase 1 dose expansion for luvelta for patients with endometrial cancers as a Mini Oral Session at ESMO 2023 - - Sutro announced a royalty monetization agreement with Blackstone Life Sciences in June 2023, under which Sutro received an upfront payment of $140 million, and is eligible to receive up to an additional $250 million in milestone payments upon the achievement of certain return thresholds - - As of June 30, 2023, Sutro had cash and investments of $358.3 million and shares ..."
07/13/2023 4 Vasquez Nicki (Chief Port. Strat & Alnce Ofcr) has filed a Form 4 on SUTRO BIOPHARMA, INC.
Txns: Paid exercise price by delivering 1,123 shares @ $4.7, valued at $5.3k
Exercised 3,250 restricted stock units @ $0
06/29/2023 4 Petree Daniel H (Director) has filed a Form 4 on SUTRO BIOPHARMA, INC.
Txns: Gifted 18,409 shares @ $0
Gifted 18,409 shares @ $0
06/12/2023 4 Hunter Heidi (Director) has filed a Form 4 on SUTRO BIOPHARMA, INC.
Txns: Granted 25,000 options to buy @ $5.12, valued at $128k
06/12/2023 4 Wigginton Jon Marc (Director) has filed a Form 4 on SUTRO BIOPHARMA, INC.
Txns: Granted 25,000 options to buy @ $5.12, valued at $128k
06/12/2023 4 Petree Daniel H (Director) has filed a Form 4 on SUTRO BIOPHARMA, INC.
Txns: Granted 25,000 options to buy @ $5.12, valued at $128k
06/12/2023 4 PANEK JAMES P (Director) has filed a Form 4 on SUTRO BIOPHARMA, INC.
Txns: Granted 25,000 options to buy @ $5.12, valued at $128k
06/12/2023 4 MATSUI CONNIE (Director) has filed a Form 4 on SUTRO BIOPHARMA, INC.
Txns: Granted 25,000 options to buy @ $5.12, valued at $128k
06/12/2023 4 Lobacki Joseph M (Director) has filed a Form 4 on SUTRO BIOPHARMA, INC.
Txns: Granted 25,000 options to buy @ $5.12, valued at $128k
06/12/2023 4 Freund John Gordon (Director) has filed a Form 4 on SUTRO BIOPHARMA, INC.
Txns: Granted 25,000 options to buy @ $5.12, valued at $128k
06/12/2023 4 Dybbs Michael (Director) has filed a Form 4 on SUTRO BIOPHARMA, INC.
Txns: Granted 25,000 options to buy @ $5.12, valued at $128k
05/15/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/15/2023 8-K Quarterly results
Docs: "Sutro Biopharma Reports First Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones - Data from the Phase 1 dose-expansion study for luveltamab tazevibulin, or luvelta, for patients with advanced ovarian cancer will be featured as an oral presentation at ASCO 2023 - - As presented at AACR 2023, STRO-003 demonstrated potent anti-tumor activity and immune-modulating properties in preclinical models, suggesting its potential to augment checkpoint blockade therapy - - As of March 31, 2023, Sutro had cash and investments of $251.5 million and shares of Vaxcyte common stock valued at $25.0 million, which together provide a projected cash runway into the second half of 2024-"
05/02/2023 4 Srinivasan Venkatesh (Chief Tech Op Officer) has filed a Form 4 on SUTRO BIOPHARMA, INC.
Txns: Granted 7,500 options to buy @ $4.58, valued at $34.4k
Granted 10,000 restricted stock units @ $0
05/02/2023 3 Srinivasan Venkatesh (Chief Tech Op Officer) has filed a Form 3 on SUTRO BIOPHARMA, INC.
04/27/2023 8-K Quarterly results
04/17/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/14/2023 8-K Quarterly results
04/14/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
03/17/2023 4 Borgman Anne Elizabeth (Chief Medical Officer) has filed a Form 4 on SUTRO BIOPHARMA, INC.
Txns: Granted 175,000 options to buy @ $5.4, valued at $945k
Granted 150,000 restricted stock units @ $0
03/07/2023 4 Shtylla Brunilda (Chief Business Officer) has filed a Form 4 on SUTRO BIOPHARMA, INC.
Txns: Paid exercise price by delivering 4,536 shares @ $5.79, valued at $26.3k
Granted 40,000 options to buy @ $5.79, valued at $231.6k
Granted 27,500 restricted stock units @ $0
Exercised 6,750 restricted stock units @ $0
Exercised 4,375 restricted stock units @ $0
03/07/2023 3 Shtylla Brunilda (Chief Business Officer) has filed a Form 3 on SUTRO BIOPHARMA, INC.
03/07/2023 3 Borgman Anne Elizabeth (Chief Medical Officer) has filed a Form 3 on SUTRO BIOPHARMA, INC.
03/07/2023 4 Vasquez Nicki (Chief Port. Strat & Alnce Ofcr) has filed a Form 4 on SUTRO BIOPHARMA, INC.
Txns: Paid exercise price by delivering 4,990 shares @ $5.79, valued at $28.9k
Granted 35,000 options to buy @ $5.79, valued at $202.7k
Granted 25,000 restricted stock units @ $0
Exercised 6,750 restricted stock units @ $0
Exercised 5,500 restricted stock units @ $0
03/07/2023 4 Hallam Trevor (Pres. Rsrch & Cf. Sctific Ofcr) has filed a Form 4 on SUTRO BIOPHARMA, INC.
Txns: Paid exercise price by delivering 7,717 shares @ $5.79, valued at $44.7k
Granted 50,000 options to buy @ $5.79, valued at $289.5k
Granted 40,000 restricted stock units @ $0
Exercised 9,750 restricted stock units @ $0
Exercised 12,500 restricted stock units @ $0
03/07/2023 4 FITZPATRICK LINDA A (Chief People & Comm. Officer) has filed a Form 4 on SUTRO BIOPHARMA, INC.
Txns: Paid exercise price by delivering 6,395 shares @ $5.79, valued at $37k
Granted 40,000 options to buy @ $5.79, valued at $231.6k
Granted 27,500 restricted stock units @ $0
Exercised 9,125 restricted stock units @ $0
Exercised 8,750 restricted stock units @ $0
03/07/2023 4 Chung Jane (Chief Commercial Officer) has filed a Form 4 on SUTRO BIOPHARMA, INC.
Txns: Paid exercise price by delivering 3,211 shares @ $5.79, valued at $18.6k
Granted 40,000 options to buy @ $5.79, valued at $231.6k
Granted 27,500 restricted stock units @ $0
Exercised 7,875 restricted stock units @ $0
03/07/2023 4 Shabbir Anik (Chief Technical Ops. Officer) has filed a Form 4 on SUTRO BIOPHARMA, INC.
Txns: Paid exercise price by delivering 6,222 shares @ $5.79, valued at $36k
Granted 40,000 restricted stock units @ $0
Exercised 7,875 restricted stock units @ $0
Exercised 8,750 restricted stock units @ $0
03/07/2023 4 ALBINI EDWARD C (CFO and Secretary) has filed a Form 4 on SUTRO BIOPHARMA, INC.
Txns: Paid exercise price by delivering 6,588 shares @ $5.79, valued at $38.1k
Granted 47,000 options to buy @ $5.79, valued at $272.1k
Granted 31,500 restricted stock units @ $0
Exercised 9,125 restricted stock units @ $0
Exercised 8,750 restricted stock units @ $0
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy